Investigational Drug Information for Evobrutinib
✉ Email this page to a colleague
What is the development status for investigational drug Evobrutinib?
Evobrutinib is an investigational drug.
There have been 19 clinical trials for Evobrutinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 10th 2019.
The most common disease conditions in clinical trials are Multiple Sclerosis, Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. The leading clinical trial sponsors are Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, and EMD Serono Research & Development Institute, Inc.
There are nine US patents protecting this investigational drug and one hundred and sixty-three international patents.
Summary for Evobrutinib
| US Patents | 9 |
| International Patents | 163 |
| US Patent Applications | 68 |
| WIPO Patent Applications | 74 |
| Japanese Patent Applications | 13 |
| Clinical Trial Progress | Phase 2 (2019-09-10) |
| Vendors | 39 |
Recent Clinical Trials for Evobrutinib
| Title | Sponsor | Phase |
|---|---|---|
| Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants | Merck KGaA, Darmstadt, Germany | Phase 1 |
| Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| DDI Study of Evobrutinib and Carbamazepine | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
Clinical Trial Summary for Evobrutinib
Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib
US Patents for Evobrutinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Evobrutinib | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| Evobrutinib | ⤷ Try a Trial | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| Evobrutinib | ⤷ Try a Trial | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidi- n-1-yl)-propenone | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| Evobrutinib | ⤷ Try a Trial | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidi- n-1-yl)-propenone | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| Evobrutinib | ⤷ Try a Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try a Trial |
| Evobrutinib | ⤷ Try a Trial | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Evobrutinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Evobrutinib | Australia | AU2012267491 | 2031-06-10 | ⤷ Try a Trial |
| Evobrutinib | Australia | AU2017235978 | 2031-06-10 | ⤷ Try a Trial |
| Evobrutinib | Brazil | BR112013030442 | 2031-06-10 | ⤷ Try a Trial |
| Evobrutinib | Canada | CA2833771 | 2031-06-10 | ⤷ Try a Trial |
| Evobrutinib | China | CN103814016 | 2031-06-10 | ⤷ Try a Trial |
| Evobrutinib | China | CN106831732 | 2031-06-10 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
